Selinexor has been shown to prolong progression-free survival in patients with TP53-mutant endometrial cancer.

Published Date: 02 Aug 2023

According to a study presented at the July 2023 meeting of the American Society for Clinical Oncology Plenary, maintenance therapy with selinexor offers long-lasting survival advantages for endometrial cancer with TP53 mutations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

2.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

3.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

4.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

5.

CDC Alerts on Dramatic Rise in Human Parvovirus B19


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot